Equillium Inc (EQ) Stock Analysis

Equillium Inc (EQ) is a publicly traded company in the HEALTHCARE sector. It trades at $2.79, carries a market capitalization of $194.74M. This page summarizes the public market data, fundamentals, and frequently asked questions for EQ, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Equillium Inc currently has a Bullish sentiment score of 0.17.

About Equillium Inc

Equillium, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, dedicated to developing novel therapeutics for severe autoimmune and inflammatory disorders that currently have no effective treatment options. Utilizing its proprietary platform, the company focuses on innovative therapies that target specific immuno-inflammatory pathways, thereby positioning itself as a leader in addressing complex diseases. With a promising pipeline of clinical candidates, Equi...

GNG Research Analysis

GNG Research scores Equillium Inc (EQ) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for EQ.

Frequently Asked Questions

Does EQ pay dividends?

Equillium Inc (EQ) does not currently pay a regular dividend.

What is EQ's market cap?

Equillium Inc (EQ) has a market capitalization of $194.74M with a current stock price of $2.79.